{"id":13532,"date":"2024-05-10T11:29:03","date_gmt":"2024-05-10T09:29:03","guid":{"rendered":"https:\/\/semmelweis.hu\/pharmacology\/?page_id=13532"},"modified":"2025-09-23T14:08:55","modified_gmt":"2025-09-23T12:08:55","slug":"kardio-immunologia-munkacsoport","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/pharmacology\/kutatas\/kardiovaszkularis-es-metabolizmus\/kardio-immunologia-munkacsoport\/","title":{"rendered":"Kardio-immunol\u00f3gia munkacsoport"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Cardio-immunology Research Group\" width=\"753\" height=\"424\" src=\"https:\/\/www.youtube.com\/embed\/pe9_BUehsng?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><iframe loading=\"lazy\" title=\"Cardio-Oncology and Cardio-Immunology Research Group\" width=\"753\" height=\"424\" src=\"https:\/\/www.youtube.com\/embed\/TkbLlAoHIpY?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<div class=\"responsive-tabs\">\n<h2 class=\"tabtitle\">Projektek<\/h2>\n<div class=\"tabcontent\">\n\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><b>Gyullad\u00e1sos \u00e9s immunol\u00f3giai folyamatok vizsg\u00e1lata kardiovaszkul\u00e1ris megbeteged\u00e9sekben<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">A kr\u00f3nikus sz\u00edvel\u00e9gtelens\u00e9g progn\u00f3zisa a modern ter\u00e1pi\u00e1s eszk\u00f6z\u00f6k \u00e9s gy\u00f3gyszerek mellett is igen rossz, a betegek mintegy fele a diagn\u00f3zist k\u00f6vet\u0151 5 \u00e9ven bel\u00fcl meghal. A betegs\u00e9g kezel\u00e9se igen nagy terhet r\u00f3 az eg\u00e9szs\u00e9g\u00fcgyi rendszerekre. A sz\u00edvel\u00e9gtelens\u00e9g sz\u00e1mos okb\u00f3l j\u00f6het l\u00e9tre, de kialakul\u00e1sa sor\u00e1n a sz\u00edvizomzat szerkezete \u00e9s funkcionalit\u00e1sa k\u00e1rosodik. Leggyakoribb okok k\u00f6z\u00e9 az iszk\u00e9mi\u00e1s sz\u00edvbetegs\u00e9g, genetikai \u00e9s gy\u00f3gyszer induk\u00e1lta (leggyakrabban tumor ellenes kemoter\u00e1pi\u00e1k) kardiomiop\u00e1ti\u00e1k tartoznak, de aritmi\u00e1k \u00e9s billenty\u0171betegs\u00e9gek is okozhatj\u00e1k a kialakul\u00e1s\u00e1t. Az elt\u00e9r\u0151 etiol\u00f3gia ellen\u00e9re a sz\u00edvel\u00e9gtelens\u00e9g progresszi\u00f3jaban fontos szerepet j\u00e1tszanak mind cellul\u00e1ris (neutrophil granulocit\u00e1k, makrof\u00e1gok, B \u00e9s T limfocit\u00e1k) mind pedig humor\u00e1lis gyullad\u00e1sos folyamatok, gyullad\u00e1skelt\u0151 citokinek, neuropeptidek, \u00edgy az IL-1\u03b2, IL-18 vagy a TNF-\u03b1, melyek jelent\u0151sen fokozz\u00e1k a sz\u00edvizomzat k\u00e1rosod\u00e1s\u00e1t.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-13655 aligncenter\" src=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-400x225.jpg\" alt=\"\" width=\"713\" height=\"401\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-400x225.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-1024x576.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-768x432.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas-753x424.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/06\/onco_cardio_kutatasi_iranyok_gyulladas.jpg 1280w\" sizes=\"auto, (max-width: 713px) 100vw, 713px\" \/><\/span><\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">Vizsg\u00e1lataink c\u00e9lja ezen sejtt\u00edpusok \u00e9s a k\u00fcl\u00f6nb\u00f6z\u0151 humor\u00e1lis faktorok ter\u00e1pi\u00e1s modul\u00e1l\u00e1s\u00e1nak vizsg\u00e1lata k\u00fcl\u00f6nb\u00f6z\u0151 sz\u00edvel\u00e9gtelens\u00e9g modellekben \u00e9s <\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>in vitro<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"> sejtalap\u00fak\u00eds\u00e9rletes rendszereken.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><b>1.1. K\u00fcl\u00f6nb\u00f6z\u0151 gyullad\u00e1sos mechanizmusok (inflammasz\u00f3ma priming \u00e9s aktiv\u00e1ci\u00f3, DNS szenzor \u00fatvonalak) szerepe \u00e9s ter\u00e1pi\u00e1s befoly\u00e1sol\u00e1si lehet\u0151s\u00e9gei sz\u00edvbetegs\u00e9gekben<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">Projektfelel\u0151s: Dr. On\u00f3di Zs\u00f3fia, Dr. M\u00f3rotz G\u00e1bor, Dr. Varga Zolt\u00e1n<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\">Az IL-1\u03b2 felszabadul\u00e1st az inflammasz\u00f3m\u00e1k szab\u00e1lyozz\u00e1k. Az inflammasz\u00f3m\u00e1k olyan multiprotein-komplexek, amelyeket k\u00fcl\u00f6nb\u00f6z\u0151 immunsejtek expressz\u00e1lnak, \u00e9s amelyek a citokinek, pl. az IL-1\u03b2 \u00e9s az IL-18 has\u00edt\u00e1s\u00e1t \u00e9s felszabadul\u00e1s\u00e1t induk\u00e1lj\u00e1k. Amikor patog\u00e9n- vagy vesz\u00e9ly-asszoci\u00e1lt mint\u00e1k jelennek meg, az immunsejtek az inflammasz\u00f3ma feh\u00e9rj\u00e9ket fokozottan expressz\u00e1lj\u00e1k, hogy felk\u00e9sz\u00fcljenek az immunv\u00e1laszra (a jelens\u00e9get inflammasz\u00f3ma &#8222;priming&#8221;-nak nevezik). Ha az intracellul\u00e1ris inflammasz\u00f3ma szenzorok (mint p\u00e9ld\u00e1ul az NLRP3, NLRC4 vagy AIM2) felismerik a specifikus mint\u00e1zatokat, az inflammasz\u00f3m\u00e1k oligomeriz\u00e1l\u00f3dnak, \u00e9s aktiv\u00e1lj\u00e1k a kaszp\u00e1z-1 enzimet, ami a citokinek has\u00edt\u00e1s\u00e1hoz vezet (ezt nevezik inflammasz\u00f3ma &#8222;aktiv\u00e1l\u00e1snak&#8221; vagy &#8222;triggerel\u00e9snek&#8221;). Kor\u00e1bbi vizsg\u00e1lataink azt mutatt\u00e1k, hogy az inflammasz\u00f3m\u00e1k jelent\u0151s szerepet j\u00e1tszhatnak a HF patomechanizmus\u00e1ban, mivel az AIM2 \u00e9s az NLRC4 inflammasz\u00f3ma szenzorok fokozott feh\u00e9rjeexpresszi\u00f3j\u00e1t tal\u00e1ltuk a sz\u00edvel\u00e9gtelen (HF) betegekb\u0151l sz\u00e1rmaz\u00f3 hum\u00e1n sz\u00edvmint\u00e1kban, amit az IL-1\u03b2 kimutat\u00e1s\u00e1val is meger\u0151s\u00edtett\u00fcnk [1, 2]. Tov\u00e1bb\u00e1 kimutattuk, hogy a probenecid &#8211; egy klinikailag alkalmazott k\u00f6szv\u00e9nyelleni gy\u00f3gyszer &#8211; jelent\u0151s gyullad\u00e1scs\u00f6kkent\u0151, k\u00fcl\u00f6n\u00f6sen inflammasz\u00f3ma inhibitor hat\u00e1ssal rendelkezik <\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"><i>in vitro<\/i><\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"> \u00e9s <\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"><i>in vivo<\/i><\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"> modellekben [1]. Irodalmi adatok szerint [3] a probenecid a pannexin-1 csatorna g\u00e1tl\u00e1s\u00e1n kereszt\u00fcl a purinerg szignaliz\u00e1ci\u00f3 modul\u00e1l\u00e1s\u00e1val hathat, amely g\u00e1tolhatja az inflammasz\u00f3ma primingot \u00e9s aktiv\u00e1ci\u00f3t is. M\u00e9g mindig nem ismert azonban, hogy a probenecid \u00e9s m\u00e1s inflammasz\u00f3ma inhibitorok pontosan mely l\u00e9p\u00e9s(ek)et g\u00e1tolhatj\u00e1k.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>C\u00e9lok:<\/i><\/span><\/span><\/p>\n<ul>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\"><span lang=\"en-US\">Sz\u00edvizomdiszfunkci\u00f3s \u00e9s sz\u00edvel\u00e9gtelen \u00e1llatmodellek seg\u00edts\u00e9g\u00e9vel karakteriz\u00e1lni a gyullad\u00e1sos \u00fatvonalak v\u00e1ltoz\u00e1sait a sz\u00edvben \u00e9s m\u00e1s sz\u00f6vetekben.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\">Komplex <\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"><i>in vitro<\/i><\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"> gy\u00f3gyszer-sz\u0171r\u00e9si platform l\u00e9trehoz\u00e1sa az inflammasz\u00f3ma inhibitorok tesztel\u00e9s\u00e9re, <\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\">Hat\u00f3s\u00e1gok \u00e1ltal m\u00e1r enged\u00e9lyezett gy\u00f3gyszerek tesztel\u00e9se a l\u00e9trehozott <\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"><i>in vitro<\/i><\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"> platformon tov\u00e1bbi <\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"><i>in vivo<\/i><\/span><\/span><span style=\"font-family: Times New Roman, serif\"><span lang=\"en-US\"> vizsg\u00e1latok c\u00e9lj\u00e1b\u00f3l.<\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>Elsaj\u00e1t\u00edthat\u00f3 k\u00e9pess\u00e9gek, m\u00f3dszerek:<\/i><\/span><\/span><\/p>\n<p><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">&#8211; in vitro protein \u00e9s nukleinsav alap\u00fa m\u00f3dszerek: Western blot, ELISA, qRT-PCR,<\/span><\/span><br \/>\n<span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">&#8211; hisztol\u00f3giai elj\u00e1r\u00e1sok (rutin hisztol\u00f3giai fest\u00e9sek, immunhisztol\u00f3gia, immunfluoreszcencia),<\/span><\/span><br \/>\n<span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">&#8211; RNS in-situ hibridiz\u00e1ci\u00f3 (RNAscope), konfok\u00e1lis mikroszk\u00f3pia, \u00e1raml\u00e1si citometria,<\/span><\/span><br \/>\n<span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">&#8211; sejtkult\u00fara kezel\u00e9s,<\/span><\/span><br \/>\n<span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">&#8211; \u00e1llatk\u00eds\u00e9rletek \u00e9s m\u0171t\u00e9ti elj\u00e1r\u00e1sok,<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><b>1.2. Immunszervek (csontvel\u0151, l\u00e9p, thymus) morfol\u00f3giai \u00e9s funkcion\u00e1lis v\u00e1ltoz\u00e1sai sz\u00edvbetegs\u00e9gekben \u2013 mechanizmusok vizsg\u00e1lata \u00e9s ter\u00e1pi\u00e1s lehet\u0151s\u00e9gek<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">Projektfelel\u0151s: Dr. On\u00f3di Zs\u00f3fia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\"><span lang=\"en-US\">A gyullad\u00e1sos \u00e9s immunsejtek homeoszt\u00e1zis\u00e1nak f\u0151 helysz\u00ednei a v\u00e9rk\u00e9pz\u0151- \u00e9s immunszervek, mint p\u00e9ld\u00e1ul a csontvel\u0151, a l\u00e9p, a thymus \u00e9s a nyirokcsom\u00f3k. Sz\u00e1mos tanulm\u00e1ny \u00e1ll rendelkez\u00e9sre a HF-betegek \u00e9s \u00e1llatok sz\u00edv\u00e9nek vagy plazm\u00e1j\u00e1nak fokozott gyullad\u00e1sos aktivit\u00e1s\u00e1r\u00f3l, azonban az extrakardi\u00e1lis szervek gyullad\u00e1sos \u00fatvonalainak megv\u00e1ltoz\u00e1sa \u00e9s k\u00f6vetkezm\u00e9nyei kev\u00e9sb\u00e9 ismertek [4]. \u00c9vek \u00f3ta ismert, hogy a sz\u00edvbetegs\u00e9gek, mint p\u00e9ld\u00e1ul az el\u0151rehaladott HF, \u00f6sszef\u00fcgg\u00e9sben \u00e1llnak a v\u00e9rk\u00e9pz\u0151szervi rendelleness\u00e9gekkel, bele\u00e9rtve az an\u00e9mi\u00e1t vagy a leukocit\u00e1k megv\u00e1ltozott sz\u00e1m\u00e1t, amelyek rosszabb progn\u00f3zissal j\u00e1rnak egy\u00fctt [5, 6]. Nemr\u00e9giben arr\u00f3l sz\u00e1moltak be, hogy a sz\u00edvbetegs\u00e9gek jelent\u0151s v\u00e1ltoz\u00e1sokat induk\u00e1lhatnak a csontvel\u0151ben, amelyek befoly\u00e1solhatj\u00e1k a v\u00e9r- \u00e9s immunsejtek termel\u00e9s\u00e9t, ami fokozott gyullad\u00e1shoz vezethet [7]. Annak ellen\u00e9re, hogy egyre t\u00f6bb publik\u00e1ci\u00f3 foglalkozik a sz\u00edvel\u00e9gtelens\u00e9ghez t\u00e1rsul\u00f3 immun- \u00e9s v\u00e9rk\u00e9pz\u0151szervi diszfunkci\u00f3val, nem \u00e1ll rendelkez\u00e9sre elegend\u0151 adat a pro-inflammatorikus k\u00f6rnyezet hat\u00e1sair\u00f3l sz\u00edvbetegs\u00e9gekben. Ez\u00e9rt a j\u00f6v\u0151ben sz\u00fcks\u00e9g van a hematopoetikus szervek gyullad\u00e1sos aktivit\u00e1s\u00e1nak r\u00e9szletes jellemz\u00e9s\u00e9re.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>C\u00e9lok:<\/i><\/span><\/span><\/p>\n<ul>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\"><span lang=\"en-US\">a gyullad\u00e1sos folyamatok vizsg\u00e1lata a sz\u00edvben \u00e9s az olyan immunszervekben, mint csontvel\u0151, thymus \u00e9s l\u00e9p,<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: 'Times New Roman', serif;font-size: 14pt\"><span lang=\"en-US\">k\u00fcl\u00f6nb\u00f6z\u0151 etiol\u00f3gi\u00e1j\u00fa (pl. transzverz\u00e1lis aorta-sz\u0171k\u00fclet vagy gy\u00f3gyszer okozta) HF eg\u00e9r- \u00e9s patk\u00e1nymodellekb\u0151l sz\u00e1rmaz\u00f3 immunszervekben a gyullad\u00e1sos \u00fatvonalak aktivit\u00e1s\u00e1nak v\u00e1ltoz\u00e1sainak felm\u00e9r\u00e9se.<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>K\u00eds\u00e9rletes megk\u00f6zel\u00edt\u00e9s, elsaj\u00e1t\u00edthat\u00f3 m\u00f3dszerek:<\/i><\/span><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>\u00c1llatmodellek<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">: A k\u00eds\u00e9rlethez patk\u00e1nyokat vagy egereket haszn\u00e1lunk. K\u00fcl\u00f6nb\u00f6z\u0151 m\u00f3dszerekkel sz\u00edvizomk\u00e1rosod\u00e1st \u00e9s \u00edgy sz\u00edvizomdiszfunkci\u00f3t okozunk, pl. infarktust, aortasz\u0171k\u00edt\u00e9ssel nyom\u00e1st\u00falterhel\u00e9ses sz\u00edvel\u00e9gtelens\u00e9get vagy kardiotoxikus gy\u00f3gyszerekkel sz\u00edvizomk\u00e1rosod\u00e1st hozunk l\u00e9tre. Az \u00e1llatokat meghat\u00e1rozott ideig ut\u00e1nk\u00f6vetj\u00fck, v\u00e9rmint\u00e1kat gy\u0171jt\u00fcnk t\u0151l\u00fck \u00e9s a sz\u00edvfunkci\u00f3t echokardiogr\u00e1fi\u00e1val vizsg\u00e1ljuk, v\u00e9g\u00fcl sz\u00f6vetmint\u00e1kat gy\u0171jt\u00fcnk t\u0151l\u00fck.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>Sejtkult\u00fara modellek<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">: A gy\u00f3gyszerek potenci\u00e1lis inflammasz\u00f3ma inhibitor hat\u00e1s\u00e1nak vizsg\u00e1lat\u00e1ra a k\u00f6vetkez\u0151 k\u00eds\u00e9rleteket v\u00e9gezz\u00fck <\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>in vitro<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">. THP1 nat\u00edv vagy ASC-GFP riporter sejtvonalakat haszn\u00e1lunk az inflammasz\u00f3ma feh\u00e9rj\u00e9k expresszi\u00f3j\u00e1nak stimul\u00e1l\u00e1s\u00e1ra (priming) \u00e9s az inflammasz\u00f3ma aktiv\u00e1ci\u00f3j\u00e1nak kiv\u00e1lt\u00e1s\u00e1ra. A kezel\u00e9s ut\u00e1n a sejteket \u00e9s a fel\u00fcl\u00fasz\u00f3kat leszedj\u00fck, homogeniz\u00e1ljuk vagy k\u00e9palkot\u00f3 elj\u00e1r\u00e1sokra el\u0151k\u00e9sz\u00edtj\u00fck. <\/span><\/span><\/span><\/li>\n<li><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>Hisztol\u00f3gia, immunhisztok\u00e9mia \u00e9s -fluoreszcencia<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">: Klasszikus sz\u00f6vettani fest\u00e9st alkalmazunk a szervi fibr\u00f3zis \u00e9s a zs\u00edrlerak\u00f3d\u00e1sok jelenl\u00e9t\u00e9nek \u00e9rt\u00e9kel\u00e9s\u00e9re. A sejtfelsz\u00edni markerek \u00e9s intracellul\u00e1ris feh\u00e9rj\u00e9k expresszi\u00f3j\u00e1nak \u00e9rt\u00e9kel\u00e9s\u00e9t, valamint kolokaliz\u00e1ci\u00f3s vizsg\u00e1latokat v\u00e9gz\u00fcnk sz\u00f6veti metszeteken. Klasszikus mikr\u00f3szk\u00f3pos elj\u00e1r\u00e1sokkal vagy konfok\u00e1lis mikroszk\u00f3pi\u00e1val t\u00f6rt\u00e9nik a k\u00e9palkot\u00e1s.<\/span><\/span><\/span><\/li>\n<li><span style=\"font-size: 14pt\"><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\"><i>In vitro molekul\u00e1ris \u00e9s biok\u00e9miai m\u00e9r\u00e9sek<\/i><\/span><\/span><span style=\"color: #1e2326\"><span style=\"font-family: Times New Roman, serif\">: A sejtek jel\u00e1tviteli v\u00e1ltoz\u00e1sait, a feh\u00e9rje- \u00e9s citokinszinteket, az enzimaktivit\u00e1sokat Western blot, qRT-PCR, ELISA, citokin array vagy enzimaktivit\u00e1si pr\u00f3b\u00e1k seg\u00edts\u00e9g\u00e9vel hat\u00e1rozzuk meg.<\/span><\/span><\/span><\/li>\n<\/ul>\n<p align=\"justify\"><span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\"><i>Referenci\u00e1k:<\/i><\/span><\/span><\/p>\n<p><span style=\"font-family: Calibri, serif;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">1. Onodi, Z., et al., <\/span><span style=\"font-family: Times New Roman, serif\"><i>AIM2-driven inflammasome activation in heart failure.<\/i><\/span><span style=\"font-family: Times New Roman, serif\"> Cardiovasc Res, 2021. <\/span><span style=\"font-family: Times New Roman, serif\"><b>117<\/b><\/span><span style=\"font-family: Times New Roman, serif\">(13): p. 2639-2651.<\/span><\/span><br \/>\n<span style=\"font-family: Calibri, serif;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">2. Kugler, S., et al., <\/span><span style=\"font-family: Times New Roman, serif\"><i>Inflammasome activation in end-stage heart failure-associated atrial fibrillation.<\/i><\/span><span style=\"font-family: Times New Roman, serif\"> ESC Heart Fail, 2022. <\/span><span style=\"font-family: Times New Roman, serif\"><b>9<\/b><\/span><span style=\"font-family: Times New Roman, serif\">(4): p. 2747-2752.<\/span><\/span><br \/>\n<span style=\"font-family: Calibri, serif;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">3. Onodi, Z., et al., <\/span><span style=\"font-family: Times New Roman, serif\"><i>Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.<\/i><\/span><span style=\"font-family: Times New Roman, serif\"> Br J Pharmacol, 2023. <\/span><span style=\"font-family: Times New Roman, serif\"><b>180<\/b><\/span><span style=\"font-family: Times New Roman, serif\">(6): p. 685-700.<\/span><\/span><br \/>\n<span style=\"font-family: Calibri, serif;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">4. Li, H., C. Chen, and D.W. Wang, <\/span><span style=\"font-family: Times New Roman, serif\"><i>Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure.<\/i><\/span><span style=\"font-family: Times New Roman, serif\"> Front Physiol, 2021. <\/span><span style=\"font-family: Times New Roman, serif\"><b>12<\/b><\/span><span style=\"font-family: Times New Roman, serif\">: p. 695047.<\/span><\/span><br \/>\n<span style=\"font-family: Calibri, serif;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">5. Anand, I.S. and P. Gupta, <\/span><span style=\"font-family: Times New Roman, serif\"><i>Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies.<\/i><\/span><span style=\"font-family: Times New Roman, serif\"> Circulation, 2018. <\/span><span style=\"font-family: Times New Roman, serif\"><b>138<\/b><\/span><span style=\"font-family: Times New Roman, serif\">(1): p. 80-98.<\/span><\/span><br \/>\n<span style=\"font-family: Calibri, serif;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">6. Sukhbaatar, N. and T. Weichhart, <\/span><span style=\"font-family: Times New Roman, serif\"><i>Iron Regulation: Macrophages in Control.<\/i><\/span><span style=\"font-family: Times New Roman, serif\"> Pharmaceuticals (Basel), 2018. <\/span><span style=\"font-family: Times New Roman, serif\"><b>11<\/b><\/span><span style=\"font-family: Times New Roman, serif\">(4).<\/span><\/span><br \/>\n<span style=\"font-family: Calibri, serif;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">7. Rohde, D., et al., <\/span><span style=\"font-family: Times New Roman, serif\"><i>Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease.<\/i><\/span><span style=\"font-family: Times New Roman, serif\"> Nat Cardiovasc Res, 2022. <\/span><span style=\"font-family: Times New Roman, serif\"><b>1<\/b><\/span><span style=\"font-family: Times New Roman, serif\">(1): p. 28-44.<\/span><\/span><br \/>\n<span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">Fig1 &#8211; Adamo, L., Rocha-Resende, C., Prabhu, S.D. et al. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 17, 269\u2013285 (2020). https:\/\/doi.org\/10.1038\/s41569-019-0315-x<\/span><\/span><br \/>\n<span style=\"color: #1e2326;font-size: 14pt\"><span style=\"font-family: Times New Roman, serif\">Fig2 &#8211; Solimando AG, Melaccio A, Vacca A, Ria R. The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu. Journal of Cancer Metastasis and Treatment. 2022; 8: 9. http:\/\/dx.doi.org\/10.20517\/2394-4722.2021.166<\/span><\/span><\/p>\n\n<\/div><h2 class=\"tabtitle\">Tagok<\/h2>\n<div class=\"tabcontent\">\n\n<p><strong>Munkacsoport-vezet\u0151:<\/strong><\/p>\n<p><a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=12953\">Dr. Guly\u00e1s-\u00d3nodi Zs\u00f3fia, PhD<\/a><\/p>\n<p><strong>PhD hallgat\u00f3:<\/strong><\/p>\n<p><a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=21252\">Kocsis M\u00e1rton<\/a><br \/>\nT\u00f3th Art\u00far, PhD<\/p>\n<p><strong>Asszisztens:<\/strong><\/p>\n<p><a href=\"https:\/\/semmelweis.hu\/telefonkonyv\/?emp_id=23648\">Jezsoviczky S\u00e1ra<\/a><\/p>\n\n<\/div><h2 class=\"tabtitle\">K\u00e9pek<\/h2>\n<div class=\"tabcontent\">\n\n\r\n        [slb_exclude]\r\n        <div class=\"row galeria-wrapper mx-0 h-auto\">\r\n            <div class=\"col-9 pl-0 pr-2\">\r\n            <span class=\"gallery-item frame\">\r\n\t\t\t\t<div class=\"galeria-left-img\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-scaled.jpg\"><img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-scaled.jpg  \r\n                            alt=\"\" \r\n                            class=\"attachment-sote-gallery-big size-sote-gallery-big\" \r\n                            srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-2048x1366.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7533-203x135.jpg 203w\" ><\/a><\/div>\r\n            <\/span>\r\n\r\n            <\/div>\r\n\r\n\t\t\t<div class=\"col-3 pl-0 pr-0\">\r\n\t\t\t\t<div class=\"galeria-right-img d-flex justify-content-between flex-column h-100 w-100 px-0 mx-0 \">\r\n                <div class=\"galeria-box\">\r\n\t\t\t\t\t<h3 class=\"galeria-title\">Gal\u00e9ria<\/h3>\r\n\t\t\t\t\t<div class=\"galeria-subtitle\">\r\n\r\n\t\t\t\t\t\t<div class=\"galeria-page-counter\"><span>5<\/span>k\u00e9p<\/div>\r\n                    <\/div> <\/div>\r\n                    <span class=\"gallery-item frame d-none d-md-flex\">\r\n\t\t\t\t\t<div class=\"galeria-small-img mt-0\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-scaled.jpg\"><img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-scaled.jpg \r\n                                alt=\"\"  \r\n                                class=\"attachment-sote-gallery-small size-sote-gallery-small\" \r\n                                srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7816-203x135.jpg 203w\" ><\/a><\/div>\r\n                    <\/span>\r\n                    <span class=\"gallery-item frame d-none d-md-flex\">\r\n\t\t\t\t\t<div class=\"galeria-small-img mt-0\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-scaled.jpg\"><img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-scaled.jpg \r\n                                alt=\"\" \r\n                                class=\"attachment-sote-gallery-small size-sote-gallery-small\" \r\n                                srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7787-203x135.jpg 203w\" ><\/a><\/div>\r\n                    <\/span>\r\n\r\n                <\/div>\r\n\r\n            <\/div>\r\n\r\n            <span class=\"gallery-item\"><div class=\"hidden\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-scaled.jpg\">\r\n        <img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-scaled.jpg alt=\"\" class=\"attachment-sote-gallery-big size-sote-gallery-big\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7656-203x135.jpg 203w\" >\r\n        <\/a><\/div><\/span><span class=\"gallery-item\"><div class=\"hidden\"><a href=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-scaled.jpg\">\r\n        <img src=https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-scaled.jpg alt=\"\" class=\"attachment-sote-gallery-big size-sote-gallery-big\" srcset=\"https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-400x267.jpg 400w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-1024x683.jpg 1024w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-768x512.jpg 768w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-1536x1024.jpg 1536w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-2048x1365.jpg 2048w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-753x502.jpg 753w, https:\/\/semmelweis.hu\/pharmacology\/files\/2024\/08\/BAL7774-203x135.jpg 203w\" >\r\n        <\/a><\/div><\/span>\r\n            <\/div>\r\n\r\n            [\/slb_exclude]\r\n\t\n<p>&nbsp;<\/p>\n<\/div><\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gyullad\u00e1sos \u00e9s immunol\u00f3giai folyamatok vizsg\u00e1lata kardiovaszkul\u00e1ris megbeteged\u00e9sekben A kr\u00f3nikus sz\u00edvel\u00e9gtelens\u00e9g progn\u00f3zisa a modern ter\u00e1pi\u00e1s eszk\u00f6z\u00f6k \u00e9s gy\u00f3gyszerek mellett is igen rossz, a betegek mintegy fele a diagn\u00f3zist k\u00f6vet\u0151 5 \u00e9ven bel\u00fcl meghal. A betegs\u00e9g kezel\u00e9se igen nagy terhet r\u00f3 az eg\u00e9szs\u00e9g\u00fcgyi rendszerekre. A sz\u00edvel\u00e9gtelens\u00e9g sz\u00e1mos okb\u00f3l j\u00f6het l\u00e9tre, de kialakul\u00e1sa sor\u00e1n a sz\u00edvizomzat szerkezete \u00e9s &hellip;<\/p>\n","protected":false},"author":102374,"featured_media":0,"parent":336,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-13532","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/13532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/users\/102374"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/comments?post=13532"}],"version-history":[{"count":10,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/13532\/revisions"}],"predecessor-version":[{"id":15098,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/13532\/revisions\/15098"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/336"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/media?parent=13532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/categories?post=13532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/tags?post=13532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}